CINECA IRIS Institutional Research Information System

FAVA, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.703
EU - Europa 3.720
AS - Asia 1.952
AF - Africa 51
SA - Sud America 46
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.511
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.641
CN - Cina 1.336
IT - Italia 679
IE - Irlanda 655
DE - Germania 479
SE - Svezia 453
FR - Francia 313
UA - Ucraina 310
FI - Finlandia 248
DK - Danimarca 189
KR - Corea 160
VN - Vietnam 155
GB - Regno Unito 96
AT - Austria 89
IN - India 83
JP - Giappone 74
PL - Polonia 67
CA - Canada 54
SG - Singapore 32
ES - Italia 28
AU - Australia 25
BE - Belgio 24
NL - Olanda 23
BR - Brasile 22
HK - Hong Kong 22
SN - Senegal 21
TR - Turchia 21
AR - Argentina 14
NG - Nigeria 14
CH - Svizzera 12
SA - Arabia Saudita 12
TW - Taiwan 11
CZ - Repubblica Ceca 10
EG - Egitto 9
MY - Malesia 8
NZ - Nuova Zelanda 8
TH - Thailandia 8
CL - Cile 6
UZ - Uzbekistan 6
BG - Bulgaria 5
IR - Iran 5
MX - Messico 5
PT - Portogallo 5
RO - Romania 5
RU - Federazione Russa 5
HR - Croazia 4
HU - Ungheria 4
JO - Giordania 4
NO - Norvegia 4
AP - ???statistics.table.value.countryCode.AP??? 3
CR - Costa Rica 3
EU - Europa 3
ID - Indonesia 3
PH - Filippine 3
PK - Pakistan 3
SI - Slovenia 3
ZA - Sudafrica 3
BT - Bhutan 2
GR - Grecia 2
IL - Israele 2
LI - Liechtenstein 2
LV - Lettonia 2
RS - Serbia 2
AM - Armenia 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MW - Malawi 1
NP - Nepal 1
PE - Perù 1
UG - Uganda 1
UY - Uruguay 1
Totale 11.511
Salva come PNG Salva come JPEG
Città #
Beijing 859
Chandler 726
Dublin 642
Ann Arbor 577
Fairfield 401
Houston 323
Ashburn 290
Villeurbanne 232
Medford 230
Princeton 199
Wilmington 198
Torino 185
Nyköping 183
Seattle 178
Woodbridge 172
Jacksonville 155
Cambridge 124
Dearborn 94
San Mateo 88
Vienna 87
Dong Ket 78
Pisa 74
Hebei 67
Warsaw 64
Hangzhou 53
Redwood City 53
Fremont 52
Nanjing 46
Turin 46
Boston 43
Düsseldorf 43
New York 39
Toronto 36
Norwalk 35
Guangzhou 31
Hefei 31
Chongqing 29
Milan 27
San Diego 21
Seoul 20
Falls Church 19
Chengdu 17
Shanghai 17
San Jose 16
Berlin 15
Brussels 15
Rome 15
Abuja 14
Nürnberg 14
Napoli 13
Phoenix 13
Pune 13
Silver Spring 13
Buenos Aires 12
Changchun 12
Jinan 12
Mountain View 12
Singapore 12
Tokyo 12
Shenyang 11
Washington 11
Wuhan 11
Collegno 10
Fuzhou 10
Hong Kong 10
Istanbul 10
Paris 10
Piemonte 10
Upper Marlboro 10
Chennai 9
Helsinki 9
Jeddah 9
Taipei 9
Zhengzhou 9
Cork 8
Nanchang 8
Redmond 8
Elsternwick 7
Florence 7
Guiyang 7
São Paulo 7
Verona 7
Ankara 6
Changsha 6
Des Moines 6
Hyderabad 6
Los Angeles 6
Nijmegen 6
Ningbo 6
Serra 6
Alessandria 5
Alpignano 5
Bangalore 5
Bangkok 5
Birmingham 5
Bologna 5
Brno 5
Central District 5
Costa Mesa 5
Edinburgh 5
Totale 7.402
Salva come PNG Salva come JPEG
Nome #
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. 389
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 264
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 256
THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 174
BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation 173
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH 171
Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways 169
PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS 165
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 164
Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. 163
Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia 155
A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML. 150
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 146
Role of Cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 139
Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1 138
Deferasirox-dependent iron chelation enhances mitochondrial dysfunction and restores p53 signaling by stabilization of p53 family members in leukemic cells 137
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 136
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice 132
Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe. 131
Role of cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 128
DROPLED DIGITAL PCR MAY HAVE A PROGNOSTIC VALUE FOR PREDICTING RELAPSE AFTER IMATINIB DISCONTINUATION 122
Milestones and Monitoring 121
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 121
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report 119
Outcome of patients with chronic phase CML treated with dasatinib or nilotinib after failure of second prior TKIs. 118
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 117
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR 115
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 112
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 108
COMPARISON OF DROPLET DIGITAL PCR AND STANDARD PCR IN CHRONIC MYELOID LEUKEMIA PATIENTS IN MR4 106
The choice of first-line chronic myelogenous leukemia treatment 100
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 96
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? 95
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 94
Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells 94
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. 93
Recommendations for the Management of CML in the Era of Second-Generation TKIs 90
IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE 86
Characterization and monitoring by droplet digital PCR of a novel BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia 86
EARLY BCR-ABL REDUCTION IS PREDICTIVE OF BETTER EVENT FREE SURVIVAL IN CHRONIC MYELOID LEUKEMIA NEWLY DIAGNOSED PATIENTS TREATED WITH ANY TKIS 83
CHARLSON COMORBIDITIES INDEX (CCI) MAY PREDICT COMPLIANCE AND DEVELOPMENT OF PLEURAL EFFUSIONS IN ELDERLY CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT PATIENTS TREATED WITH DASATINIB 82
Development and targeted use of nilotinib in chronic myeloid leukemia. 82
IMATINIB DISCOTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON 28 UNSELECTED PATIENTS 81
Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation. 80
Consistency Of RQPCR Analysis Results In Peripheral Blood and Bone Marrow Samples In Chronic Myeloid Leukemia Patients: Relevance From The Practical and Logistic Point Of View 79
A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience. 79
Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia 78
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 77
Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. 75
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 75
Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms 75
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience 75
Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. 74
Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia 74
CARDIOVASCULAR EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FIRST-LINE: AN ANALISYS OF THE GIMEMA CML WP 71
A Retrospective Real-Life Analysis of Chronic Myeloid Leukemia Patients in Suboptimal Response to Imatinib. 71
BCR-ABL1 mutation not equal ponatinib resistance 71
Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts 71
CHRONIC MYELOID LEUKEMIA WITH EXTREME THROMBOCYTOCIS AT THE DIAGNOSIS: A NEW SUBSET 70
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia? 68
A CRITICAL COMPARISON OF SOKAL, EURO, AND EUTOS RISK SCORES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS 68
Advances in the biology and therapy of patients with chronic myeloid leukaemia. 68
COEXISTENCE OF A JAK2 MUTATED CLONE MAY CAUSE HEMATOLOGIC RESISTANCE (HRES) TO TIROSYN-KINASE INHIBITORS (TKI) IN CHRONIC MYELOID LEUKEMIA (CML) 67
STANDARD AND HIGH SENSITIVITY MOLECULAR ANALYSIS IN CHRONIC MYELOID LEUKEMIA PATIENTS CANDIDATE TO DISCONTINUATION OF TYROSINE KINASE INHIBITORS 67
Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor 67
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 67
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 66
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 66
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity 66
Mitoxantrone-related acute myeloid leukaemia, induced one year after the discontinuation of mitoxantrone therapy 64
The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. 64
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 64
Philadelphia-positive lymphoblastic lymphoma: A case report and review of the literature 63
Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation 61
Treatment-free remission in chronic myeloid leukemia harboring atypical BCRABL1 transcripts 60
One Step Quantitative Molecular Approach for Detection of BCR/ABL Translocation and for Monitoring and Follow up of the Minimal Residual Disease in CML Patients Under Tyrosine Kines Inhibitors Treatment. 59
Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline 59
To Swab or Not to Swab? The Lesson Learned in Italy in the Early Stage of the COVID-19 Pandemic 59
Clinical significance of early molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate. 56
Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis 55
Second-Generation Tyrosine Kinase Inhibitors Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant 55
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia. 55
The Q-LAMP method represents a valid and rapid alternative for the detection of the BCR-ABL1 rearrangement in Philadelphia-positive Leukemias 54
Update on emerging treatments for chronic myeloid leukemia 53
Single nucleotide polymorphisms of ABCB1 gene influence on intracellular concentrations of dasatinib. 52
Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib. 52
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? 52
Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response 51
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 51
The Biology of CML Supports SecondGeneration TKIs as Frontline Treatment 50
Practical monitoring of chronic myelogenous leukemia: when to change treatment 49
Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia 49
Ponatinib for chronic myeloid leukaemia: Future perspectives 49
SECOND GENERATION TYROSINE KINASE INHIBITORS CAN INDUCE COMPLETE MOLECULAR RESPONSE IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANT 49
Clinical Use of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia (CML) 48
Advances in the treatment of chronic myeloid leukemia 48
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation 48
FISH-MLL abnormalities in patients in Acute Myeliodblastic Leukemia and association with FLT3 and MLL internal duplication. 47
A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia 47
Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia 46
Totale 9.335
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.749
article - articoli 0
book - libri 0
conference - conferenze 14.866
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019388 0 0 0 0 0 0 0 0 0 90 219 79
2019/20201.506 51 61 52 231 85 203 139 110 151 156 123 144
2020/20211.838 162 143 126 106 223 74 96 102 122 125 240 319
2021/20222.465 139 258 140 175 149 106 214 159 90 177 387 471
2022/20232.375 285 194 66 182 178 700 189 134 227 55 113 52
2023/2024748 123 176 57 54 73 140 35 41 3 46 0 0
Totale 12.154